Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CRHBP | P24387 | 2/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14206482 | 0.98 | CXCR4 (0.50) | CXCR4APEX1MEN1KMT2AKDM4E | |
| SCHEMBL17465542 | 0.91 | APEX1 (0.43) | CXCR4APEX1MEN1KMT2AKDM4E | |
| SCHEMBL27349434 | 0.83 | CXCR4 (0.53) | CXCR4APEX1KDM4ELMNAHTR2C | |
| SCHEMBL9207672 | 0.83 | CXCR4 (0.58) | CXCR4APEX1KDM4ELMNAHTR2C | |
| SCHEMBL27349957 | 0.81 | CXCR4 (0.51) | CXCR4KDM4ELMNAHTR2C | |
| SCHEMBL18911328 | 0.81 | CXCR4 (0.44) | CXCR4APEX1KDM4ESMN1; SMN2HTR2C | |
| SCHEMBL8235408 | 0.81 | CXCR4 (0.56) | CXCR4APEX1KDM4ELMNAHTR2C | |
| SCHEMBL1673295 | 0.81 | CXCR4 (0.56) | CXCR4APEX1KDM4ELMNAHTR2C | |
| SCHEMBL29520740 | 0.81 | CXCR4 (0.56) | CXCR4APEX1KDM4ELMNAHTR2C | |
| SCHEMBL27351084 | 0.80 | CXCR4 (0.54) | CXCR4APEX1KDM4ELMNAHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133654-A1 | NEW CRYPTATE-TYPE (BICYCLIC) CHELATORS AND THEIR USE AS LIGANDS FOR MN(II)-BASED MRI CONTRAST AGENTS, 52MN-BASED PET DIAGNOSTIC AGENTS, AND 64/67CU(II)-ISOTOPE-BASED PET DIAGNOSTIC AND THERAPEUTIC AGENTS | DEBRECENI EGYETEM (HU) | 2025-06-26 | — | — | WO | disclosed |
| US-10377783-B2 | Methods and compounds for enhancing contrast in magnetic resonance imaging (MRI) | BROCK UNIVERSITY (CA) | 2019-08-13 | — | — | US | disclosed |
| US-20160362434-A1 | METHODS AND COMPOUNDS FOR ENHANCING CONTRAST IN MAGNETIC RESONANCE IMAGING (MRI) | BROCK UNIVERSITY (CA) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377783-B2 | Methods and compounds for enhancing contrast in magnetic resonance imaging (MRI) | PPIP5K2, FABP7, MPI | CXCR4 2022/4885APEX1 3634/4885MEN1 27/4885 |
| US-20160362434-A1 | METHODS AND COMPOUNDS FOR ENHANCING CONTRAST IN MAGNETIC RESONANCE IMAGING (MRI) | PPIP5K2, FABP7, MPI | CXCR4 2022/4885APEX1 3634/4885MEN1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.